ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,287.30
0.07%
Dow Jones
44,910.65
0.42%
Gold vs US Dollar
2,649.87
0.00%
Brent Oil
71.98
0.00%
Bitcoin
96,426.30
-0.01%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. AMEX
  6. Can Fite BioPharma Ltd (CANF)

  7. Can Fite BioPharma Ltd (CANF) News

Can Fite BioPharma (CANF)

Can Fite BioPharma Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:AMEX:CANF
DateTimeSourceHeadlineSymbolCompany
14/11/202421:48Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]AMEX:CANFCan Fite BioPharma Ltd
11/11/202412:00GlobeNewswire Inc.Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical TrialAMEX:CANFCan Fite BioPharma Ltd
04/11/202412:09Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
04/11/202412:08GlobeNewswire Inc.Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in AustraliaAMEX:CANFCan Fite BioPharma Ltd
18/10/202413:23Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
18/10/202413:06GlobeNewswire Inc.Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with PiclidenosonAMEX:CANFCan Fite BioPharma Ltd
09/10/202411:03Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
09/10/202411:00GlobeNewswire Inc.FDA Grants Orphan Drug Designation to Can-Fite’s Namodenoson for Pancreatic CancerAMEX:CANFCan Fite BioPharma Ltd
07/10/202411:00GlobeNewswire Inc.Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on October 29AMEX:CANFCan Fite BioPharma Ltd
24/09/202411:05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
24/09/202411:00GlobeNewswire Inc.Projected Income of $325M to Can-Fite Over the Next 10 Years After Vetbiolix Exercised its Option and Licensed Piclidenoson for Veterinary OsteoarthritisAMEX:CANFCan Fite BioPharma Ltd
16/09/202411:07Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
16/09/202411:00GlobeNewswire Inc.Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of HealthAMEX:CANFCan Fite BioPharma Ltd
09/09/202404:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessAMEX:CANFCan Fite BioPharma Ltd
06/09/202420:30Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]AMEX:CANFCan Fite BioPharma Ltd
06/09/202404:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessAMEX:CANFCan Fite BioPharma Ltd
30/08/202420:18Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
30/08/202420:18Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersAMEX:CANFCan Fite BioPharma Ltd
30/08/202420:16Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementAMEX:CANFCan Fite BioPharma Ltd
30/08/202420:15Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]AMEX:CANFCan Fite BioPharma Ltd
29/08/202412:46Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
29/08/202412:15GlobeNewswire Inc.Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical StudiesAMEX:CANFCan Fite BioPharma Ltd
12/08/202410:45Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
09/08/202410:07Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
08/08/202423:01GlobeNewswire Inc.Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross ProceedsAMEX:CANFCan Fite BioPharma Ltd
29/07/202411:03Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
29/07/202411:00GlobeNewswire Inc.Can-Fite Provides Namodenoson Patent UpdateAMEX:CANFCan Fite BioPharma Ltd
17/07/202411:00GlobeNewswire Inc.Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on August 8AMEX:CANFCan Fite BioPharma Ltd
11/07/202411:05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
11/07/202411:00GlobeNewswire Inc.Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic CancerAMEX:CANFCan Fite BioPharma Ltd
 Showing the most relevant articles for your search:AMEX:CANF

Your Recent History

BOV
ESSE7L
Essencia Agropecuaria PNC
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved

    BLACK FRIDAY

    ADVFN

    Celebrating 25 years Est 1999-2024

    Save up to 50%* for Silver

    1 year 30%, 2 years 40% and *3 years 50%

    *Across 3 years £903.96 only £451.98